1. CYRAMZA® is a registered trademark owned by Eli Lilly and its subsidiaries or related companies, or licensed to Eli Lilly and its subsidiaries.2. F.M Johnston, Mr. Beckman. Updated stomach cancer management. Latest Oncology Reports 2019 (21), 673.M. Orditura, G. Galizia, V. Sforza et al. Treatment of Stomach Cancers, World Journal of Gastroenterology 2014 (20), 1635-16494. A. Bass, V. Thorsson, I.
Shmulevich et al. Complete molecular characterization of gastenocarcinoma. Nature 2014 (513), 202-2095. T. G. Hall, Y. Yu, S. Eathiraj et al. Preclinical activity of ARQ 087, a new inhibitor for FGFR dysregulation. PLoS ONE 2016, 11 (9), e01625946. R.
Porta, R. Borea, A. Coelho et al. FGFR a promising drug target in cancer: molecular biology and new drugs. Oncology/Hematology Reviews 2017 (113), 256-2677. T. Helsten, S. Elkin, E. Arthur et al.
The FGFR landscape for cancer: analysis of 4,853 tumors by sequencing the next generation. Clinical Cancer Research 2016 (22), 259-2678. P. McSheehy, F. Bachmann, N. Forster-Gross et al. Derazantinib (DZB): an FGFR/CSF1R inhibitor that is active in PDX models of urothel cancer. Molecular Cancer Therapeutics 2019 (18), 12 supplement, pp. LB-C129. Mr. A.
Cannarile, M. Weisser, W. Jacob et al. Factor 1 receptor inhibitors (CSF1R) in cancer treatment. Journal for ImmunoTherapy of Cancer 2017, 5:5310. Y. Zhu, B. L. Knolhoff, M. A. Meyer et al.
CSF1/CSF1R Blockage reprograms tumor-infiltrated macrophages and improves response to T-Zell Checkpoint immunotherapy in pancreatic cancer models. Cancer Research 2014 (74), 5057-506911. E. Peranzoni, J. Lemoine, L. Vimeux et al. Macrophages prevent CD8-T cells from reaching tumor cells and limit the effectiveness of anti-PD-1 treatment. Proceedings of the National Academy of Science of the United States of America 2018 (115), E4041-E405012. V. Mazzaferro, B. F. El-Rayes, M.
Droz dit Busset et al. Derazantinib (ARQ 087) in case of FGFR2-positive gene intrahepatischem cholangiocarcinoma. British Journal of Cancer 2019 (120), 165-171. ClinicalTrials.gov Signature: NCT0175292013. FIDES-01: ClinicalTrials.gov qualifiers: NCT0323031814. FIDES-02: ClinicalTrials.gov qualifiers: NCT0404561315. FIDES-03: ClinicalTrials.gov ID: NCT04604132 Linda Hanna, Managing Director of Scottish Enterprise, added: “This agreement with AstraZeneca is a fantastic confirmation of Symbiosis`s capabilities and highlights Scotland`s global reputation for life sciences and manufacturing. We have been working with Colin and his team for many years, and we look forward to monitoring their progress in developing a vaccine against the global pandemic. Basilea Pharmaceutica Ltd.
(SIX: BSLN) announced today that it has granted clinical cooperation and a delivery agreement with Eli Lilly and Company for the use of the anti-VEGFR2 ramucirumab antibody (CYRAMZA®) 1 in the current multi-cohorte phase, FIDES-03, with the Azantinib FGFR inhibitor in patients with advanced stomach cancer with the FGFR genaire. Basilea is the sponsor of the study and Lilly will collaborate on clinical aspects and provide clinical supply of ramucirumab. Colin MacKay, founder and CEO of Symbiosis, said: “Our team is very proud to make a very important contribution to the global fight against COVID-19 and to the urgent efforts to achieve an effective vaccine. With our long direct experience in the production of such drugs and vaccines for clinical trials and commercial markets, we are pleased to be able to use our know-how and competitiveness to accelerate the development of this vaccine for AstraZeneca and add value to the project. The agreement follows AstraZeneca`s recent announcement that it will enter into a licensing agreement with Oxford University for the development, production and distribution of the AZD1222 vaccine candidate, formerly known as ChAdOx1 nCoV-19. The vaccine candidate is currently undergoing clinical trials at several sites in the UK.